Xencor, Inc. (NASDAQ:XNCR) Stock Rated “Moderate Buy” by Wall Street Brokerages

Xencor, Inc. (NASDAQ:XNCR) has been assigned an average rating of “Moderate Buy” from the eleven brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $34.00.

XNCR has been the subject of several recent research reports. JPMorgan Chase & Co. raised their price target on Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a research report on Thursday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research report on Monday, September 21st. Wells Fargo & Company started coverage on Xencor in a research note on Wednesday. They set an “overweight” rating and a $55.00 price objective on the stock. Wedbush lifted their price objective on Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Finally, Raymond James Financial upped their target price on shares of Xencor from $40.00 to $46.00 and gave the company a “strong-buy” rating in a report on Tuesday, September 1st.

Xencor Price Performance

XNCR stock opened at $24.95 on Friday. The company’s 50 day simple moving average is $24.11 and its 200-day simple moving average is $16.94. The firm has a market capitalization of $1.86 billion, a PE ratio of -11.50 and a beta of 0.88. Xencor has a 12 month low of $10.38 and a 12 month high of $30.61.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The firm had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same period in the previous year, the firm posted ($0.41) EPS. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Xencor will post -3.05 earnings per share for the current year.

Hedge Funds Weigh In On Xencor

Several institutional investors and hedge funds have recently modified their holdings of XNCR. BlackRock Inc. acquired a new stake in Xencor during the second quarter worth approximately $219,785,000. Primecap Management Co. CA acquired a new position in Xencor in the 2nd quarter valued at $163,919,000. BVF Inc. IL lifted its stake in shares of Xencor by 160.3% during the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after purchasing an additional 4,393,579 shares during the period. Legal & General Group Plc boosted its holdings in shares of Xencor by 2.8% during the fourth quarter. Legal & General Group Plc now owns 1,308,088 shares of the biopharmaceutical company’s stock worth $20,027,000 after purchasing an additional 35,088 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Xencor by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after purchasing an additional 45,599 shares during the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company that develops engineered antibodies and cytokine therapeutics for the treatment of cancer, autoimmune diseases and other serious medical conditions. The company’s platform is designed to modify antibody properties, including immune-system activation, half-life and biological activity, to create differentiated therapeutic candidates.

Xencor’s proprietary XmAb technology supports its internal research programs and collaborations with other biopharmaceutical companies.